Universitas Krisnadwipayana Indonesia, Jakarta, Indonesia.
Faculty of Biology and Ecology, Yanka Kupala State University of Grodno, Grodno, Belarus.
Hum Immunol. 2021 Oct;82(10):733-745. doi: 10.1016/j.humimm.2021.06.011. Epub 2021 Jul 1.
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 is associated with excessive inflammation, as a main reason for severe condition and death. Increased inflammatory cytokines and humoral response to SARS-CoV-2 correlate with COVID-19 immunity and pathogenesis. Importantly, the levels of pro-inflammatory cytokines that increase profoundly in systemic circulation appear as part of the clinical pictures of two overlapping conditions, sepsis and the hemophagocytic syndromes. Both conditions can develop lethal inflammatory responses that lead to tissue damage, however, in many patients hemophagocytic lymphohistiocytosis (HLH) can be differentiated from sepsis. This is a key issue because the life-saving aggressive immunosuppressive treatment, required in the HLH therapy, is absent in sepsis guidelines. This paper aims to describe the pathophysiology and clinical relevance of these distinct entities in the course of COVID-19 that resemble sepsis and further highlights two effector arms of the humoral immune response (inflammatory cytokine and immunoglobulin production) during COVID-19 infection.
导致 COVID-19 的严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 与过度炎症有关,这是导致严重病情和死亡的主要原因。炎症细胞因子和体液对 SARS-CoV-2 的反应增加与 COVID-19 的免疫和发病机制有关。重要的是,在全身循环中显著增加的促炎细胞因子水平作为两种重叠疾病即脓毒症和噬血细胞综合征的临床表现的一部分出现。这两种情况都可能发生致命的炎症反应,导致组织损伤,然而,在许多患者中,噬血细胞性淋巴组织细胞增多症 (HLH) 可以与脓毒症区分开来。这是一个关键问题,因为 HLH 治疗中需要的救命性积极免疫抑制治疗在脓毒症指南中是缺失的。本文旨在描述 COVID-19 病程中类似于脓毒症的这些不同实体的病理生理学和临床相关性,并进一步强调 COVID-19 感染期间体液免疫反应的两个效应臂(炎症细胞因子和免疫球蛋白产生)。